Cargando…
Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers
OBJECTIVES: The aim of this study was to assess the effects of concomitant administration of erenumab and sumatriptan on resting blood pressure, pharmacokinetics, safety, and tolerability in healthy subjects. METHODS: In this phase 1, parallel-group, one-way crossover, double-blind, placebo-controll...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348461/ https://www.ncbi.nlm.nih.gov/pubmed/29783863 http://dx.doi.org/10.1177/0333102418776017 |
_version_ | 1783390107013742592 |
---|---|
author | de Hoon, Jan Van Hecken, Anne Vandermeulen, Corinne Herbots, Marissa Kubo, Yumi Lee, Ed Eisele, Osa Vargas, Gabriel Gabriel, Kristin |
author_facet | de Hoon, Jan Van Hecken, Anne Vandermeulen, Corinne Herbots, Marissa Kubo, Yumi Lee, Ed Eisele, Osa Vargas, Gabriel Gabriel, Kristin |
author_sort | de Hoon, Jan |
collection | PubMed |
description | OBJECTIVES: The aim of this study was to assess the effects of concomitant administration of erenumab and sumatriptan on resting blood pressure, pharmacokinetics, safety, and tolerability in healthy subjects. METHODS: In this phase 1, parallel-group, one-way crossover, double-blind, placebo-controlled study, healthy adult subjects were randomized (1:2) to receive either intravenous placebo and subcutaneous sumatriptan 12 mg (i.e. two 6-mg injections separated by 1 hour) or intravenous erenumab 140 mg and subcutaneous sumatriptan 12 mg. Blood pressure was measured pre-dose and at prespecified times post-dose. The primary endpoint was individual time-weighted averages of mean arterial pressure, measured from 0 hours to 2.5 hours after the first dose of sumatriptan. Pharmacokinetic parameters for sumatriptan were evaluated by calculating geometric mean ratios (erenumab and sumatriptan/placebo and sumatriptan). Adverse events and anti-erenumab antibodies were also evaluated. RESULTS: A total of 34 subjects were randomized and included in the analysis. Least squares mean (standard error) time-weighted averages of mean arterial pressure were 87.4 (1.0) mmHg for the placebo and sumatriptan group and 87.4 (1.2) mmHg for the erenumab and sumatriptan group. Mean difference in mean arterial pressure between groups was −0.04 mmHg (90% confidence interval: −2.2, 2.1). Geometric mean ratio estimates for maximum plasma concentration of sumatriptan was 0.95 (90% confidence interval: 0.82, 1.09), area under the plasma concentration–time curve (AUC) from time 0 to 6 hours was 0.98 (90% confidence interval: 0.93, 1.03), and AUC from time 0 to infinity was 1.00 (90% confidence interval: 0.96, 1.05). No clinically relevant safety findings for co-administration of sumatriptan and erenumab were identified. CONCLUSION: Co-administration of erenumab and sumatriptan had no additional effect on resting blood pressure or on pharmacokinetics of sumatriptan. Trial registration: ClinicalTrials.gov, NCT02741310. |
format | Online Article Text |
id | pubmed-6348461 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-63484612019-02-15 Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers de Hoon, Jan Van Hecken, Anne Vandermeulen, Corinne Herbots, Marissa Kubo, Yumi Lee, Ed Eisele, Osa Vargas, Gabriel Gabriel, Kristin Cephalalgia Original Articles OBJECTIVES: The aim of this study was to assess the effects of concomitant administration of erenumab and sumatriptan on resting blood pressure, pharmacokinetics, safety, and tolerability in healthy subjects. METHODS: In this phase 1, parallel-group, one-way crossover, double-blind, placebo-controlled study, healthy adult subjects were randomized (1:2) to receive either intravenous placebo and subcutaneous sumatriptan 12 mg (i.e. two 6-mg injections separated by 1 hour) or intravenous erenumab 140 mg and subcutaneous sumatriptan 12 mg. Blood pressure was measured pre-dose and at prespecified times post-dose. The primary endpoint was individual time-weighted averages of mean arterial pressure, measured from 0 hours to 2.5 hours after the first dose of sumatriptan. Pharmacokinetic parameters for sumatriptan were evaluated by calculating geometric mean ratios (erenumab and sumatriptan/placebo and sumatriptan). Adverse events and anti-erenumab antibodies were also evaluated. RESULTS: A total of 34 subjects were randomized and included in the analysis. Least squares mean (standard error) time-weighted averages of mean arterial pressure were 87.4 (1.0) mmHg for the placebo and sumatriptan group and 87.4 (1.2) mmHg for the erenumab and sumatriptan group. Mean difference in mean arterial pressure between groups was −0.04 mmHg (90% confidence interval: −2.2, 2.1). Geometric mean ratio estimates for maximum plasma concentration of sumatriptan was 0.95 (90% confidence interval: 0.82, 1.09), area under the plasma concentration–time curve (AUC) from time 0 to 6 hours was 0.98 (90% confidence interval: 0.93, 1.03), and AUC from time 0 to infinity was 1.00 (90% confidence interval: 0.96, 1.05). No clinically relevant safety findings for co-administration of sumatriptan and erenumab were identified. CONCLUSION: Co-administration of erenumab and sumatriptan had no additional effect on resting blood pressure or on pharmacokinetics of sumatriptan. Trial registration: ClinicalTrials.gov, NCT02741310. SAGE Publications 2018-05-21 2019-01 /pmc/articles/PMC6348461/ /pubmed/29783863 http://dx.doi.org/10.1177/0333102418776017 Text en © International Headache Society 2018 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Articles de Hoon, Jan Van Hecken, Anne Vandermeulen, Corinne Herbots, Marissa Kubo, Yumi Lee, Ed Eisele, Osa Vargas, Gabriel Gabriel, Kristin Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers |
title | Phase 1, randomized, parallel-group, double-blind, placebo-controlled
trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan
on blood pressure in healthy volunteers |
title_full | Phase 1, randomized, parallel-group, double-blind, placebo-controlled
trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan
on blood pressure in healthy volunteers |
title_fullStr | Phase 1, randomized, parallel-group, double-blind, placebo-controlled
trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan
on blood pressure in healthy volunteers |
title_full_unstemmed | Phase 1, randomized, parallel-group, double-blind, placebo-controlled
trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan
on blood pressure in healthy volunteers |
title_short | Phase 1, randomized, parallel-group, double-blind, placebo-controlled
trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan
on blood pressure in healthy volunteers |
title_sort | phase 1, randomized, parallel-group, double-blind, placebo-controlled
trial to evaluate the effects of erenumab (amg 334) and concomitant sumatriptan
on blood pressure in healthy volunteers |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348461/ https://www.ncbi.nlm.nih.gov/pubmed/29783863 http://dx.doi.org/10.1177/0333102418776017 |
work_keys_str_mv | AT dehoonjan phase1randomizedparallelgroupdoubleblindplacebocontrolledtrialtoevaluatetheeffectsoferenumabamg334andconcomitantsumatriptanonbloodpressureinhealthyvolunteers AT vanheckenanne phase1randomizedparallelgroupdoubleblindplacebocontrolledtrialtoevaluatetheeffectsoferenumabamg334andconcomitantsumatriptanonbloodpressureinhealthyvolunteers AT vandermeulencorinne phase1randomizedparallelgroupdoubleblindplacebocontrolledtrialtoevaluatetheeffectsoferenumabamg334andconcomitantsumatriptanonbloodpressureinhealthyvolunteers AT herbotsmarissa phase1randomizedparallelgroupdoubleblindplacebocontrolledtrialtoevaluatetheeffectsoferenumabamg334andconcomitantsumatriptanonbloodpressureinhealthyvolunteers AT kuboyumi phase1randomizedparallelgroupdoubleblindplacebocontrolledtrialtoevaluatetheeffectsoferenumabamg334andconcomitantsumatriptanonbloodpressureinhealthyvolunteers AT leeed phase1randomizedparallelgroupdoubleblindplacebocontrolledtrialtoevaluatetheeffectsoferenumabamg334andconcomitantsumatriptanonbloodpressureinhealthyvolunteers AT eiseleosa phase1randomizedparallelgroupdoubleblindplacebocontrolledtrialtoevaluatetheeffectsoferenumabamg334andconcomitantsumatriptanonbloodpressureinhealthyvolunteers AT vargasgabriel phase1randomizedparallelgroupdoubleblindplacebocontrolledtrialtoevaluatetheeffectsoferenumabamg334andconcomitantsumatriptanonbloodpressureinhealthyvolunteers AT gabrielkristin phase1randomizedparallelgroupdoubleblindplacebocontrolledtrialtoevaluatetheeffectsoferenumabamg334andconcomitantsumatriptanonbloodpressureinhealthyvolunteers |